Trial Profile
Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2015 New trial record